

## About VCU Massey Cancer Center

VCU Massey Cancer Center is among the top 4 percent of cancer centers in the country to be designated by the National Cancer Institute to lead and shape America's cancer research efforts. Working with all kinds of cancers, Massey conducts every form of cancer research, including basic science, translational, clinical and population sciences research; provides state-of-the-art cancer treatments and cutting-edge clinical trials; serves as a vital resource for oncology education, teaching and training; and promotes cancer prevention. Since 1974, Massey has been an internationally recognized center of excellence. Massey provides award-winning cancer care at multiple sites throughout Virginia by leading cancer sub-specialists and offers one of the largest cancer clinical trial menus as well as a statewide network that brings trials to communities across the commonwealth. Its 1,000-plus researchers, clinicians and staff members are dedicated to improving the quality of human life by discovering, developing, delivering and teaching effective means to prevent, detect, treat and ultimately cure cancer.

Visit Massey online at [massey.vcu.edu](http://massey.vcu.edu) or call **877-4-MASSEY** for more information.



Welcome to VCU Massey Cancer Center's  
8th Annual

**CANCER SYMPOSIUM**

**April 5, 2019**

Hilton Richmond Hotel & Spa in Short Pump  
12042 West Broad Street  
Richmond, Virginia 23233

Dear guests,

It is my pleasure once again to welcome all of you to VCU Massey Cancer Center's Cancer Symposium.

We hope you will enjoy hearing from our visiting cancer expert, Dr. Jason Luke, assistant professor of medicine at the University of Chicago, and our Massey experts, Drs. Harry D. Bear and Gary L. Simmons.

We look forward to engaging with you in various topics focusing on immunotherapies in cancer clinical research.

We hope that this symposium encourages productive discussion and that you can benefit from the information you learn and apply it to your practice.

Sincerely,



Gordon D. Ginder, M.D.  
Director and Lipman Chair in Oncology,  
VCU Massey Cancer Center

## Learning Objectives

- Understand the landscape of how immune response indicators impact prognosis and predict responses in breast cancer.
  - Learn about recent data on the clinical impact of immune therapy for breast cancer.
  - Learn about a Massey/VCU Phase II neoadjuvant immunotherapy trial for breast cancer patients.
- Learn about new FDA-approved immunotherapy CAR T-cell therapies and their advantages in the treatment of some incurable cancers.
  - Discuss future directions of CAR T-cell research and how Rx algorithms change.
- Recognize the impact of gut microbiome diversity and dysbiosis on human disease.
  - Identify the gut microbiome as a potential predictive biomarker and therapeutic target in cancer immunotherapy.
  - Understand the deleterious influence of anti-bacterial antibiotics on cancer immunotherapy outcomes.

## Target Audience

Our target audience for this symposium is physicians and nurse practitioners specializing in oncology.

## Accreditation and Educational Credits

VCU Health Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

VCU Health Continuing Medical Education designates this live activity for a maximum of **3.0 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## Medical Director of Community Oncology and Clinical Research Affiliations



### **Khalid Matin, M.D., F.A.C.P.**

Medical Director of Community Oncology and Clinical Research Affiliations and Member of the Developmental Therapeutics Research Program at VCU Massey Cancer Center; Associate Professor of Internal Medicine, Division of Hematology, Oncology and Palliative Care at the VCU School of Medicine

Dr. Matin is a board-certified medical oncologist and clinical researcher who specializes in the study and treatment of gastrointestinal (GI) cancers. He has developed several clinical trials for GI cancers and has served as the principal investigator and co-investigator on various colorectal and lung cancer trials. Dr. Matin oversees Massey's partnerships with third-party hospitals and oncology practices and manages the clinical trials program for the statewide

Clinical Research Affiliation Network.

Dr. Matin received his medical degree from Aga Khan University Medical College in Pakistan before completing a residency at Hennepin County Medical Center and a fellowship at the University of Pittsburgh Cancer Institute.



VCU Massey Cancer Center Goodwin Research Laboratory

# VCU Massey Cancer Center CANCER SYMPOSIUM AGENDA

Welcome

3-3:05 p.m.

**Gordon D. Ginder, M.D.**

Immunotherapy for Breast Cancer  
and a Neoadjuvant Window Trial

3:05-4:05 p.m.

**Harry D. Bear, M.D., Ph.D.**

CAR T-cell therapy

4:05-5:05 p.m.

**Gary L. Simmons, D.O.**

Break

5:05-5:15 p.m.

The Impact of the Fecal Microbiome  
on Cancer Immunotherapy

5:15-6:15 p.m.


**Jason Luke, M.D., F.A.C.P.**

Closing Remarks

6:15-6:20 p.m.

**Khalid Matin, M.D., F.A.C.P.**

## About the Presenters



### **Gordon D. Ginder, M.D.**


Director, Eric and Jeanette Lipman Chair in Oncology and member of the Cancer Molecular Genetics research program at VCU Massey Cancer Center; professor of internal medicine in the Division of Hematology, Oncology and Palliative Care, affiliate professor in the Departments of Human and Molecular Genetics and Microbiology and Immunology at the VCU School of Medicine

Dr. Ginder has served as director of VCU Massey Cancer Center since 1997. In this position, he oversees a cancer center designated by the National Cancer Institute (NCI) that provides award-winning cancer care and oncology education and conducts ground-breaking research to discover new ways to prevent, treat and ultimately cure cancer. He also manages a research laboratory where he focuses on regulating genes that are critical to immune cells killing cancer cells. A board-certified medical hematologist-oncologist, Dr. Ginder actively treats patients,

specializing in blood and lymph node cancers and bone marrow transplantation.

Dr. Ginder was elected to both the American Society for Clinical Research and the Association of American Physicians. He has served on numerous review boards for the National Institutes of Health (NIH) and the American Cancer Society, and is a member of several professional societies.

Dr. Ginder received his undergraduate degree from the University of Illinois and his medical degree from Johns Hopkins University. He trained in internal medicine at Case Western Reserve University Hospital and in molecular genetics at the NIH, and he completed a fellowship at the University of Iowa.



### **Harry D. Bear, M.D., Ph.D.**


Medical director of the Breast Health Program, Walter Lawrence, Jr. Distinguished Professor in Oncology, chair of the Protocol Review & Monitoring Committee and member of the Developmental Therapeutics research program at VCU Massey Cancer Center; professor and chair of the Division of Surgical Oncology in the Department of Surgery and professor of microbiology and immunology at the VCU School of Medicine

Dr. Bear is an internationally recognized expert in the treatment of breast cancer as well as melanoma and sarcoma. His research interests include basic tumor immunology and T cell biology, pre-clinical and clinical studies of immunotherapy, translational clinical research trials and breast cancer treatment trials. He has long been involved with clinical research trials, serving on the Board of Directors of the National Surgical Adjuvant Breast & Bowel Project

(NSABP) and honored by the NSABP in 2009 with the Distinguished Investigator Lifetime Achievement Award. In 2018, he served as president of the Richmond Academy of Medicine's (RAM).

Dr. Bear leads the Division of Surgical Oncology at the VCU School of Medicine and the Breast Health Program at Massey. He completed his undergraduate degree at Yale University, his medical and Ph.D. degrees at VCU School of Medicine and his residencies at Harvard Medical School-affiliated Brigham and Women's Hospital in Boston and the University of Glasgow in Scotland. He completed his fellowship in surgical oncology at VCU Medical Center.

## About the Presenters



### **Gary L. Simmons, D.O.**

Deputy director of the Cellular Immunotherapies and Transplant Program at VCU Massey Cancer Center; assistant professor of internal medicine in the Division of Hematology, Oncology & Palliative Care at the VCU School of Medicine

Dr. Simmons is the deputy director of the Cellular Immunotherapies and Transplant Program at VCU Massey Cancer Center, which provides collaborative and comprehensive care for pediatric and adult patients with a variety of blood and bone marrow disorders.

Dr. Simmons received his D.O. from the College of Osteopathic Medicine at University of New England in Biddeford, Maine. Subsequently, he pursued a residency in internal medicine and a fellowship in hematology/oncology at the VCU School of Medicine.

He is a member of the American Society of Hematology (ASH) and the American Society of Blood and Marrow Transplant (ASBMT). Dr. Simmons has received several awards, including Excellence in Teaching at the VCU School of Medicine for his work as an assistant professor of internal medicine in the Division of Hematology, Oncology & Palliative Care.



### **Jason J. Luke, M.D., F.A.C.P.**

Assistant professor of medicine in the Department of Hematology/Oncology at the University of Chicago

Dr. Luke specializes in the management of patients with melanoma and early phase drug development (particularly novel immunotherapeutics and biomarkers of immunotherapy activity).

Dr. Luke has been a leading national investigator on clinical trials of immunotherapy agents including but not limited to anti-PD1/L1, CTLA4, LAG3, TIM3, GITR, OX40, CD137, CD40, inhibitors of indoleamine-dioxygenase (IDO), adenosine A2a receptor and arginase, as well as agonists of STING and oncolytic virus.

Dr. Luke's research focuses on using large scale informatics to advance the field of cancer immunotherapy. Dr. Luke received his M.D. from Rosalind Franklin University of Medicine and Science in Chicago. He then pursued his internship and residency at the Boston University Medical Center followed by medicine and medical oncology fellowships at Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center in New York City.

Following fellowship, Dr. Luke was a tenure-track, Type 1 Instructor in Medicine at Harvard Medical School as well as Staff Physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital in Boston.

Dr. Luke is actively involved in several professional societies including the Society for Melanoma Research, the Society for Immunotherapy of Cancer, American Association for Cancer Research and the American Society for Clinical Oncology (ASCO). Dr. Luke has served as the chair of the education committee and as a member of the scientific committee for the melanoma track of the ASCO annual meeting.

Dr. Luke has received several awards including the Melanoma Research Foundation Humanitarian Award, Department of Defense Career Development Award, Paul Calabresi Career Development in Clinical Oncology Award (K12), ASCO Merit Award as well as Young Investigator Awards from the Melanoma Research Alliance, the Cancer Research Foundation and the Conquer Cancer Foundation of ASCO. Dr. Luke's research has been supported by ASCO, the National Comprehensive Cancer Network and the National Cancer Institute.